Ponatinib treatment promotes arterial thrombosis and hyperactive platelets

Q: What does this research mean for the field?

Ponatinib therapy increases arterial thrombosis and platelet reactivity, an effect that can be reversed by concurrent treatment with pioglitazone. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Alona Merkulova; S. C. Mitchell; Evi X. Stavrou; Gabriel L Forbes; Alvin H. Schmaier

doi:10.1182/bloodadvances.2019000034

August 5, 2019Blood AdvancesOpen Access

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Key Points Ponatinib therapy heightens arterial thrombosis and platelet reactivity. Concurrent pioglitazone treatment reverses heightened thrombosis risk and platelet reactivity induced by ponatinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Merkulova et al. (2019) studied this question.

synapsesocial.com/papers/6a1d29b37f448865515de687 https://doi.org/10.1182/bloodadvances.2019000034

View Full Paper

Ask AI

Bookmark

Share

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets

Ask about this paper

Abstract

Discussion

Cite This Study

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading